Lung Neuroendocrine Neoplasm clinical trials at UC Health
1 research study open to eligible people
Experimental medicine and whole brain radiation therapy to treat patients with brain metastases from non-small cell lung cancer
“Study looking at radiation therapy and experimental medicine, VX-970 for treatment of lung cancer with metastases to brain”
open to eligible people ages 18 years and up
This phase I trial studies the side effects and best dose of ATR kinase inhibitor M6620 (VX-970) when given together with whole brain radiation therapy in treating patients with non-small cell lung cancer, small cell lung cancer, or neuroendocrine tumors that have spread from the original (primary) tumor to the brain. ATR kinase inhibitor M6620 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving ATR kinase inhibitor M6620 together with radiation therapy may be a better treatment for non-small cell lung cancer, small cell lung cancer, or neuroendocrine tumors.
at UC Davis